Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Summary

This is a prospective non-randomized efficacy trial of olaparib maintenance therapy after frontline treatment with platinum-based therapy in advanced ovarian cancer patients with BRCAwt, homologous recombination deficient (HRD) disease.

Timeline

Start

2024-01-17

Primary completion

2027-12-31

Completion

2029-12-31

Outcome

Outcome not reported

Stopped: “Sponsor terminated due to Olaparib losing patent”

Drugs

Indications